Jupiter, Florida, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical...
Jupiter, Florida, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical...
LONDON, Feb. 3, 2025 /PRNewswire/ - MYndspan, a pioneer in consumer brain health technology, and BIOS Health, a leader in...
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
ASCO recognizes the hospital's commitment to quality care, safety standards, culture of excellence and patient outcomes. TAMPA, Fla., Jan. 30, 2025...
Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical toolsMALVERN, Pa., Jan. 29, 2025 (GLOBE...
CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the...
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023;AUSTEDO® - exceeding $1.6...
ONWARD ARC-EX System for spinal cord injury is now available for purchase through VA Federal Supply Schedule and GSA Advantage...
PLEASANTON, Calif., Jan. 28, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced...
Revolutionizing care from minimally invasive surgery to comprehensive outpatient services RIYADH, Saudi Arabia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- King...
Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up...
Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective measures of drug efficacy and...
The Regeneron Science Talent Search Celebrates and Rewards Today's Most Talented Young Minds Driving Innovation and Progress through Scientific Exploration...
The first investigational FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+,...
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
This collaboration merges advanced analytics with EEG technology for next-level emotional insights CAMBRIDGE, England, Jan. 21, 2025 /PRNewswire/ -- Neuro...
The pricing determination for HCPCS code E3200 will take effect on April 1, 2025PORTLAND, Maine, Jan. 16, 2025 /PRNewswire/ -- MedRhythms,...
Strategic hire underscores Emmes Group's growth and commitment to biopharma market ROCKVILLE, Md., Jan. 16, 2025 /PRNewswire/ -- Emmes Group®,...
Servier to leverage Google Cloud AI across R&D, production, and distribution, accelerating digital transformation to benefit patients.These new advancements in...